Gert-Jan Braunstahl

Gert-Jan Braunstahl

Auto-generated profile, based on publicly available information

Gert-Jan Braunstahl

Department of Pulmonology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2001 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
GBGert-Jan Braunstahl
Gert-Jan Braunstahl
SOShelley E. Overbeek
Shelley E. Overbeek
AKAlex KleinJan
Alex KleinJan
JPJan-Bas Prins
Jan-Bas Prins
HHHenk C. Hoogsteden
Henk C. Hoogsteden
WFWytske J. Fokkens
Wytske J. Fokkens

1 June 2000 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
GBGert-Jan Braunstahl
Gert-Jan Braunstahl
AKAlex Kleinjan
Alex Kleinjan
SOShelley E. Overbeek
Shelley E. Overbeek
JPJan-Bas Prins
Jan-Bas Prins
HHHenk C. Hoogsteden
Henk C. Hoogsteden
WFWytske J. Fokkens
Wytske J. Fokkens
Allergic rhinitis and asthma often coexist and share a genetic background. Pathophysiologic connections between the nose and lungs are still not entirely understood. This study was undertaken to compare allergic inflammation and clinical findings in the upper and lower airways after segmental bronchial provocation (SBP) in nonasthmatic allergic rhinitis patients. Eight nonasthmatic, grass pollen-sensitive patients with allergic rhinitis and eight healthy controls were included. Bronchial biopsies and blood samples were taken before (T0) and 24 h (T24) after SBP. Nasal biopsies were obtained at T0, 1 h after SBP (T1), and T24. Immunohistochemical staining was performed for eosinophils (BMK13), interleukin (IL)-5, and eotaxin. The number of eosinophils increased in the challenged and unchallenged bronchial mucosa (p < 0.05) and in the blood (p = 0.03) of atopic subjects at T24. We detected an increase of BMK13-positive and eotaxin-positive cells in the nasal lamina propria and enhanced expression of IL-5 in the nasal epithelium of atopic subjects only at T24 (p < 0.05). SBP induced nasal and bronchial symptoms as well as reductions in pulmonary and nasal function in the allergic group. No significant changes could be observed in healthy controls. The study shows that SBP in nonasthmatic allergic rhinitis patients results in peripheral blood eosinophilia, and that SBP can induce allergic inflammation in the nose.

1 March 2008 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
WBW.I. de Boer
W.I. de Boer
HSH.S. SharmaH.S. Sharma
H.S. SharmaH.S. Sharma
SBS.M.I. BaelemansS.M.I. Baelemans
S.M.I. BaelemansS.M.I. Baelemans
HHH.C. HoogstedenH.C. Hoogsteden
H.C. HoogstedenH.C. Hoogsteden
BLB.N. LambrechtB.N. Lambrecht
B.N. LambrechtB.N. Lambrecht
GBG.J. BraunstahlG.J. Braunstahl
G.J. BraunstahlG.J. Braunstahl
Epithelial cells form a tight barrier against environmental stimuli via tight junctions (TJs) and adherence junctions (AJs). Defects in TJ and AJ proteins may cause changes in epithelial morphology and integrity and potentially lead to faster trafficking of inflammatory cells through the epithelium. Bronchial epithelial fragility has been reported in asthmatic patients, but little is known about the expression of TJ and AJ proteins in asthma. We studied epithelial expression of zonula occludens-1 (ZO-1) and AJ proteins E-cadherin, α-catenin, and β-catenin in bronchial biopsies from nonatopic nonasthmatic (healthy) subjects (n = 14), and stable atopic asthmatic subjects (n = 22) at baseline conditions. Immunostaining for these proteins was semi-quantified for separate cellular compartments. E-cadherin, α-catenin and β-catenin were present in the cellular membrane and less in the cytoplasm. Only β-catenin was present in the nucleus in agreement with its potential function as transcription factor. ZO-1 was present in the apicolateral membrane of superficial cells. α-Catenin expression was significantly lower in subjects with asthma than without and correlated inversely with numbers of eosinophils within the epithelium. ZO-1 and E-cadherin expression were significantly lower in asthmatic than in nonasthmatic subjects. Expression of β-catenin was not different. Our results suggest that the lower epithelial α-catenin, E-cadherin and (or) ZO-1 expression in patients with atopic asthma contributes to a defective airway epithelial barrier and a higher influx of eosinophils in the epithelium.

1 August 2013 in Respiratory Medicine
Verified
Journal Article
Open access
GBG.-J. Braunstahl
G.-J. Braunstahl
CCC.-W. Chen
C.-W. Chen
RMR. Maykut
R. Maykut
PGP. Georgiou
P. Georgiou
GPG. Peachey
G. Peachey
JBJ. Bruce
J. Bruce
Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of outcomes in real-world clinical practice is needed to provide a complete understanding of the benefits of omalizumab treatment. eXpeRience was a 2-year, international, single-arm, open-label, observational registry that evaluated real-world effectiveness, safety and use of omalizumab therapy in 943 patients with uncontrolled persistent allergic asthma. Effectiveness variables (physician's Global Evaluation of Treatment Effectiveness [GETE], and change from baseline in exacerbation rate, symptoms, rescue medication use, and oral corticosteroid [OCS] use) were evaluated at pre-specified time-points. Safety data were also recorded. By physician's GETE, 69.9% of patients were responders to omalizumab after 16 (±1) weeks. The proportion of patients with no clinically significant exacerbations increased from 6.8% during the 12-month pre-treatment period to 54.1% and 67.3% at Months 12 and 24, respectively. Symptoms and rescue medication use at Month 24 were reduced by >50% from baseline. Maintenance OCS use was lower at Month 24 (14.2%) compared with Month 12 (16.1%) and baseline (28.6%). Overall, omalizumab had an acceptable safety profile. The results from eXpeRience indicate that omalizumab was associated with improvements in outcomes in patients with uncontrolled persistent allergic asthma; these improvements were consistent with the results of clinical trials.

30 April 2015 in Thorax
Verified
Journal Article
Open access
PDF file
AHAstrid van Huisstede
Astrid van Huisstede
ARArjan Rudolphus
Arjan Rudolphus
MCManuel Castro Cabezas
Manuel Castro Cabezas
LBLaser Ulas Biter
Laser Ulas Biter
GGGert-Jan van de Geijn
Gert-Jan van de Geijn
ASA. van Schadewijk
A. van Schadewijk
Background The pathogenesis of asthma in obese subjects is poorly understood and has been described as a specific phenotype in these patients. Weight loss improves asthma control and lung function. Whether this improvement is the result of better mechanical properties of the airways or decreased systemic and bronchial inflammation remains unclear. Methods A longitudinal study in obese patients with asthma (bariatric surgery and asthma group (BS+A), n=27) and obese control (bariatric surgery without asthma group (BS−A), n=39) subjects undergoing bariatric surgery, and obese patients with asthma without intervention (no bariatric surgery and asthma group (NBS+A), n=12). Lung function, asthma control, cellular infiltrates in bronchial biopsies and circulating markers of systemic inflammation were measured during follow up at 3, 6 and 12 months. Results Bariatric surgery resulted in a profound weight loss at 12 months. In the BS+A group as well as the BS−A group FEV1, functional residual capacity, total lung capacity improved, whereas FEV1/FVC only improved in the BS−A group. In addition, Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire, inhaled corticosteroid use and PD20 improved in BS+A, whereas in the NBS+A group only ACQ improved. Small airway function R5–R20 improved in both surgery groups, however the change in the BS+A group was greater, resulting in a comparable R5–R20 between BS+A and BS−A at 12-month follow-up. Besides improvement of systemic inflammation (high sensitivity C-reactive protein, adiponectin and leptin) after BS, only a decrease in mast cell numbers was detectable in the BS+A group. Conclusions Bariatric surgery improved small airway function, decreased systemic inflammation and number of mast cells in the airways. These effects could explain the improvement of asthma control, quality of life and lung function. Therefore bariatric surgery, in addition to all other positive effects, also improves asthma in subjects with morbid obesity. Trial registration number 3204.

1 September 2001 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
GBGert-Jan Braunstahl
Gert-Jan Braunstahl
SOShelley E. Overbeek
Shelley E. Overbeek
WFWytske J. Fokkens
Wytske J. Fokkens
AKAlex Kleinjan
Alex Kleinjan
AMALAN R. McEUEN
ALAN R. McEUEN
JPJan–Bas Prins
Jan–Bas Prins
Mast cells and basophils are cells that play an important role in the initiation and control of allergic inflammation in asthma and rhinitis. This study was undertaken to determine the presence and dynamics of mast cells and basophils in the nasal and bronchial mucosa of allergic rhinitis patients after segmental bronchial provocation (SBP). Eight nonasthmatic, grass pollen-allergic rhinitis patients and eight healthy controls were included. Bronchial and nasal biopsies, as well as blood samples, were taken before (T0) and 24 h (T24) after SBP. Immunohistochemical staining was performed for mast cells (tryptase and chymase; phenotypes MCT, MCTC, MCC) and basophils (BB1). In the bronchial mucosa, the number of BB1+ cells increased significantly (p < 0.05) in allergic rhinitis patients after SBP. In the nasal mucosa, the numbers of MCC and MCTC cells decreased significantly, whereas the numbers of [BB1+] cells increased significantly in allergic rhinitis patients after SBP (p < 0.05). In blood, the number of basophils decreased (p < 0.05) and the level of interleukin (IL)-5 increased (p < 0.05) in atopic patients after SBP. No significant changes could be observed in healthy controls. This study shows that SBP in nonasthmatic allergic rhinitis patients reduces numbers of mast cells in the nose as a result of enhanced degranulation. At the same time, there is evidence for an influx of basophils from the blood into the nasal and bronchial mucosae. Keywords: bronchoprovocation; asthma; rhinitis; biopsy; inflammation